Sustained efficacy over 1 year of treatment with erenumab: results from the extension phase of the STRIVE study in episodic migraine

被引：0

作者：

Goadsby, Peter J. ^{[1
]}

Reuter, Uwe ^{[2
]}

Hallstrom, Yngve ^{[3
]}

Broessner, Gregor ^{[4
]}

Bonner, Jo H. ^{[5
]}

Zhang, Feng ^{[6
]}

Sapra, Sandhya ^{[6
]}

Chou, Denise E. ^{[6
]}

Klatt, Jan ^{[7
]}

Picard, Hernan ^{[6
]}

Lenz, Robert A. ^{[6
]}

Mikol, Daniel D. ^{[6
]}

机构：

[1] Kings Coll Hosp London, NIHR Wellcome Trust Kings Clin Res Facil, London, England

[2] Charite Univ Med Berlin, Dept Neurol, Berlin, Germany

[3] St Gorans Univ Hosp, Neuro Ctr, Stockholm, Sweden

[4] Med Univ Innsbruck, Headache Outpatient Clin, Dept Neurol, Innsbruck, Austria

[5] Mercy Res, St Louis, MO USA

[6] Amgen Inc, Thousand Oaks, CA 91320 USA

[7] Novartis Pharma AG, Basel, Switzerland

来源：

JOURNAL OF HEADACHE AND PAIN | 2018年 / 19卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P20

引用

下载

页数：1

共 50 条

[31] Efficacy and safety of erenumab in episodic migraine patients with 2-4 prior preventive treatment failures: Results from the Phase 3b LIBERTY study
Reuter, Uwe
Goadsby, Peter J.
Lanteri-Minet, Michel
Ferrari, Michel
Wen, Shihua
Klatt, Jan
JOURNAL OF HEADACHE AND PAIN, 2018, 19
[32] Efficacy and Safety of Erenumab in Episodic Migraine Patients with 2-4 Prior Preventive Treatment Failures: Results from the Phase 3b LIBERTY Study
Goadsby, P. J.
Lanteri-Minet, M.
Ferrari, M.
Wen, S.
Klatt, J.
HEADACHE, 2018, 58 : 77 - 77
[33] EFFICACY AND SAFETY OF ERENUMAB IN EPISODIC MIGRAINE PATIENTS WITH 2-4 PRIOR PREVENTIVE TREATMENT FAILURES: RESULTS FROM THE PHASE 3B LIBERTY STUDY
Reuter, U.
Goadsby, P. J.
Lanteri-Minet, M.
Ferrari, M. D.
Wen, S.
Hours-Zesiger, P.
Klatt, J.
CEPHALALGIA, 2018, 38 : 60 - 60
[34] Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine
Ashina, Messoud
Goadsby, Peter J.
Reuter, Uwe
Silberstein, Stephen
Dodick, David
Rippon, Gregory A.
Klatt, Jan
Xue, Fei
Chia, Victoria
Zhang, Feng
Cheng, Sunfa
Mikol, Daniel D.
CEPHALALGIA, 2019, 39 (11) : 1455 - 1464
[35] Long-term Safety and Tolerability of Erenumab: Three-plus Year Results from an Ongoing Open-label Extension Study in Episodic Migraine
Ashina, M.
Goadsby, P.
Silberstein, S. D.
Dodick, D.
Rippon, G.
Klatt, J.
Zhang, F.
Cheng, S.
Mikol, D.
HEADACHE, 2018, 58 : 72 - 73
[36] Long-term safety and tolerability of erenumab: Three-plus year results from an ongoing open-label extension study in episodic migraine
Ashina, Messoud
Goadsby, Peter J.
Reuter, Uwe
Silberstein, Stephen
Dodick, David
Rippon, Gregory A.
Klatt, Jan
Zhang, Feng
Cheng, Sunfa
Mikol, Daniel D.
JOURNAL OF HEADACHE AND PAIN, 2018, 19
[37] MAINTENANCE OF CLINICAL RESPONSE TO ERENUMAB (AMG334) IN EPISODIC MIGRAINE: COMPLETE ONE YEAR RESULTS FROM AN ONGOING OPEN-LABEL EXTENSION STUDY
Ashina, M.
Dodick, D.
Goadsby, P. J.
Reuter, U.
Silberstein, S.
Zhang, F.
Cheng, S.
Mikol, D.
Lenz, R. A.
CEPHALALGIA, 2016, 36 : 13 - 13
[38] Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study
Smith, Timothy R.
Janelidze, Marina
Chakhava, George
Cady, Roger
Hirman, Joe
Allan, Brent
Pederson, Susan
Smith, Jeff
Schaeffler, Barbara
CLINICAL THERAPEUTICS, 2020, 42 (12) : 2254 - +
[39] Sustained benefit of monthly erenumab versus daily oral preventives in episodic migraine patients from APPRAISE study
Gil-Gouveia, R.
Dolezil, D.
Paemeleire, K.
Stepien, A.
Stude, P.
Lopez, C.
Stites, T.
Ritter, S.
Babanrao, Pisal C.
Snellman, J.
Ferraris, M.
Pozo-Rosich, P.
HEADACHE, 2023, 63 : 169 - 169
[40] Sustained benefit of monthly erenumab versus daily oral preventives in episodic migraine patients from APPRAISE study
Gil-Gouveia, R.
Dolezil, D.
Paemeleire, K.
Stepien, A.
Stude, P.
Lopez, C.
Stites, T.
Ritter, S.
Pisal, C.
Snellman, J.
Ferraris, M.
Pozo-Rosich, P.
EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 272 - 272

← 1 2 3 4 5 →